Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published 30 July 2010 Volume 2010:6 Pages 665—669


Review by Single-blind

Peer reviewer comments 2

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

COSEHC global vascular risk management quality improvement program: rationale and design

Carlos M Ferrario, Michael A Moore, William Bestermann Jr, et al

Vascular Health and Risk Management 2010, 6:1135-1145

Published Date: 13 December 2010

Aliskiren and valsartan combination therapy for the management of hypertension

Benjamin J Epstein

Vascular Health and Risk Management 2010, 6:711-722

Published Date: 11 August 2010

Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases

Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al

Vascular Health and Risk Management 2010, 6:613-618

Published Date: 14 July 2010

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al

Vascular Health and Risk Management 2010, 6:571-578

Published Date: 5 July 2010

Predictors of obstructive sleep apnea in males with metabolic syndrome

Nikolaos Papanas, Paschalis Steiropoulos, Evangelia Nena, et al

Vascular Health and Risk Management 2010, 6:281-286

Published Date: 20 April 2010

Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients

Pongsathorn Gojaseni, Angkana Phaopha, Worawon Chailimpamontree, et al

Vascular Health and Risk Management 2010, 6:157-165

Published Date: 11 March 2010